Global HIV Drugs Market

Report ID : 1092 | Published : 2021-07-23 | Pages: 140 | Format:

Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV). The virus damages the immune system and thus interferes with the body’s ability to fight organisms that cause disease. HIV attacks immune cells, specifically CD-4 cells, and makes the body susceptible to infections and other diseases.

AIDS is a life-threatening and chronic disease that can be transmitted from one person to another through various routes, including sexual intercourse, direct injection with HIV-contaminated drugs, needles, syringes, blood or blood products, and from HIV-infected mothers to fetuses. As of now, no cure for AIDS. However, antiretroviral regimens (ARVs) are recommended for patients with HIV as it can dramatically slow the disease progression as well as prevent other infections and complications.

The increasing prevalence of HIV/AIDS worldwide catalyzes the growth of the global HIV drugs market. According to UNAIDS, in 2019, the total number of patients with HIV/AIDS was around 38 million across the globe. The adult and children population was 36.2 and 1.8 million, respectively.

Additionally, several initiatives are undertaken by governments/associations/organizations in respective countries and globally to educate and raise awareness, availability of generic HIV drugs, and new drug development and regulatory approvals for HIV treatment are expected to drive the market further. For instance, in March 2020, ViiV Healthcare, the subsidiary of GlaxoSmithKline, received regulatory approval for its long-acting regimen for the treatment of HIV; CABENUVA by Health Canada.

The Global HIV drugs market is segmented on the basis of product and region. Based on the product, the market is divided into Zolgensma, Atripla, Biktarvy, Complera, Delstrigo, Descovy, Dovato, Genvoya, Isentress, Juluca, Odefsey, Stribild, Symtuza, Tivicay, Triumeq, Trogarzo, Truvada, Cabotegravir/Rilpivirine, Fostemsavir, Leronlimab and Others.

Based on the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market in 2019, followed by Europe and Asia Pacific. On the other hand, the Asia Pacific is projected to have the highest growth rate during the forecast period.

The key players in the market are Gilead Sciences, ViiV Healthcare, Janssen, Merck & Co., Bristol-Myers Squibb, TaiMed Biologics, CytoDyn, Boehringer Ingelheim International GmbH,  AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan among others.

 

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global HIV Drugs Market Snapshot

Chapter 4. Global HIV Drugs Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Clinical Trial/Pipeline Analysis

4.5. Industry Analysis – Porter’s Five Forces Analysis

4.6. Clinical Trial Analysis 2019

4.7. COVID 19 Impact Analysis

Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis

5.1. Product Type & Market Share, 2020 & 2028

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Product:

5.2.1. Atripla

5.2.2. Biktarvy

5.2.3. Complera

5.2.4. Delstrigo

5.2.5. Descovy

5.2.6. Dovato

5.2.7. Genvoya

5.2.8. Isentress

5.2.9. Juluca

5.2.10. Odefsey

5.2.11. Stribild

5.2.12. Symtuza

5.2.13. Tivicay

5.2.14. Triumeq

5.2.15. Trogarzo

5.2.16. Truvada

5.2.17. Cabotegravir/Rilpivirine

5.2.18. Fostemsavir

5.2.19. Leronlimab

5.2.20. Others

Chapter 6. HIV Drugs Market Segmentation 3: Regional Estimates & Trend Analysis

6.1. North America

6.1.1. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by product, 2020-2028

6.1.2. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by country, 2020-2028

6.1.2.1. U.S.

6.1.2.2. Canada

6.2. Europe

6.2.1. Europe HIV Drugs Market revenue (US$ Million) by product, 2020-2028

6.2.2. Europe HIV Drugs Market revenue (US$ Million) by country, 2020-2028

6.2.2.1. Germany

6.2.2.2. Poland

6.2.2.3. France

6.2.2.4. Italy

6.2.2.5. Spain

6.2.2.6. UK

6.2.2.7. Rest of Europe

6.3. Asia Pacific

6.3.1. Asia Pacific HIV Drugs Market revenue (US$ Million) by product, 2020-2028

6.3.2. Asia Pacific HIV Drugs Market revenue (US$ Million) by country, 2020-2028

6.3.2.1. China

6.3.2.2. India

6.3.2.3. Japan

6.3.2.4. Australia

6.3.2.5. Rest of Asia Pacific

6.4. Latin America

6.4.1. Latin America HIV Drugs Market revenue (US$ Million) by product, (US$ Million)

6.4.2. Latin America HIV Drugs Market revenue (US$ Million) by country, (US$ Million) 2020-2028

6.4.2.1. Brazil

6.4.2.2. Rest of Latin America

6.5. MEA

6.5.1. MEA revenue HIV Drugs Market revenue (US$ Million) by product, (US$ Million) 2020-2028

6.5.2. MEA revenue HIV Drugs Market revenue (US$ Million) by country, (US$ Million) 2020-2028

6.5.2.1. South Africa

6.5.2.2. Rest of MEA

Chapter 7. Competitive Landscape

7.1. Major Mergers and Acquisitions/Strategic Alliances

7.2. Company Profiles

7.2.1. Gilead Sciences

7.2.2. ViiV Healthcare

7.2.3. Janssen

7.2.4. Bristol-Myers Squibb

7.2.5. TaiMed Biologics

7.2.6. CytoDyn

7.2.7. Boehringer Ingelheim International GmbH

7.2.8. Merck & Co. Inc.

7.2.9. AbbVie

7.2.10. F. Hoffmann-La Roche Ltd.

7.2.11. Teva Pharmaceutical Industries Ltd.

7.2.12. Cipla Limited

7.2.13. Daiichi Sankyo

7.2.14. Emcure

7.2.15. Hetero Drugs

7.2.16. Mylan

7.2.17. Shantou Huatai Pharmaceutical Co., Ltd.

7.2.18. Shengzhen Chongway Biotechnology Co., Ltd.

7.2.19. Other Prominent Player

Global HIV Drugs Market Segmentation:

 

Global HIV Drugs Market Revenue (US$ Mn), by Product, 2019-2030

  • Zolgensma
  • Atripla
  • Biktarvy
  • Complera
  • Delstrigo
  • Descovy
  • Dovato
  • Genvoya
  • Isentress
  • Juluca
  • Odefsey
  • Stribild
  • Symtuza
  • Tivicay
  • Triumeq
  • Trogarzo
  • Truvada
  • Cabotegravir/Rilpivirine
  • Fostemsavir
  • Leronlimab
  • Others

Global HIV Drugs Market Revenue (US$ Mn), By Region,2019-2030

North America HIV Drugs Market Revenue (US$ Mn), by Country, 2019-2030

  • U.S.
  • Canada

Europe HIV Drugs Market Market Revenue (US$ Mn), by Country, 2019-2030

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific HIV Drugs Market Revenue (US$ Mn), by Country, 2019-2030

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America HIV Drugs Market Revenue (US$ Mn), by Country, 2019-2030

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa HIV Drugs Market Revenue (US$ Mn), by Country,2019-2030

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients